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Objective - To develop and validate a prognostic model to predict deterioration in health-
related quality of life (dHRQoL) in older general practice patients with at least one chronic 
condition and one chronic prescription. 
Study design and setting - We used individual participant data from five cluster-randomized 
trials conducted in the Netherlands and Germany to predict dHRQoL, defined as a decrease in 
EQ-5D-3L index score of ≥5 % after six-month follow-up in logistic regression models with 
stratified intercepts to account for between-study heterogeneity. The model was validated 
internally, and by using internal-external cross-validation (IECV). 
Results – In 3,582 patients with complete data, of whom 1,046 (29.2 %) showed deterioration 
in HRQoL, 12/87 variables were selected that were related to single (chronic) conditions, 
inappropriate medication, medication underuse, functional status, well-being and HRQoL. 
Bootstrap internal validation showed a C-statistic of 0.71 (0.69 to 0.72), and a calibration slope 
of 0.88 (0.78 to 0.98). In the IECV loop, the model provided a pooled C-statistic of 0.68 (0.65 to 
0.70) and calibration-in-the-large of 0 (-0.13 to 0.13). HRQoL/functionality had the strongest 
prognostic value. 
Conclusion – The model performed well in terms of discrimination, calibration, and 
generalizability and might help clinicians identify older patients at high-risk of dHRQoL.  
Registration - PROSPERO ID: CRD42018088129 
Keywords –  
Multimorbidity, polypharmacy, elderly, patient-centred care, quality of life, functional status, 
prognostic model. 
Running title 
A prognostic model to predict deterioration in health-related quality of life in older patients 
with multimorbidity and polypharmacy. 
Word count 
3671 74 
WHAT IS NEW 75 
Key findings 76 
The PROPERmed prognostic model of future deterioration in health-related quality of life in 77 
older patients with multiple conditions and medications performed well in discrimination, 78 
calibration, and showed promising generalizability. 79 
The strongest predictors in the model were health-related quality of life and functional status 80 
at baseline. 81 
82 
What does this add to what is already known? 83 
PROPERmed-dHRQoL is the first prognostic model to predict deterioration in health-related 84 
quality of life in older patients with multiple conditions and medications that is based on an 85 
individual participant data meta-analysis. 86 
87 
What is the implication, what should change now? 88 
External validation studies should confirm generalizability beyond internal-external cross-89 
validation. 90 
Measures of health-related quality of life and functional status at baseline, which proved to be 91 
the two prognostic variables that are of outstanding relative importance in the prognostic 92 
model, might help physicians to detect patients with multimorbidity and polypharmacy at risk 93 
for a potentially preventable deterioration. 94 
INTRODUCTION 95 
In aging populations, the increased incidence and severity of multiple (chronic) conditions (two 96 
or more) leads to deterioration in health-related quality of life (dHRQoL) (1). Patients with 97 
multiple conditions usually have several drug prescriptions (five or more), which increases the 98 
risk of overuse, underuse and misuse of medications (2). Potential consequences, such as falls, 99 
cognitive decline, loss of autonomy, and hospital admissions, are often severe and may 100 
contribute to dHRQoL, a key patient-reported outcome and one of the most relevant in older 101 
life (3–5).  102 
Complex drug regimens and high treatment burden make the management of multimorbidity 103 
a significant challenge for physicians (6). They are also expensive for health care systems 104 
worldwide because they lead to an increase of health care utilization and cost (7). However, 105 
not all patients with multiple morbidities need complex care (8). As the multimorbid 106 
population is heterogeneous, it would be helpful to identify patients at high risk of dHRQoL 107 
because those with high baseline risk and/or higher severity of disease may generally be 108 
expected to benefit more from (complex) interventions (9). Furthermore, risk stratification 109 
may help allocate resources to the high-risk patients that are expected to benefit most from 110 
targeted interventions (10–12). 111 
Prognostic models are generally considered to be important tools to help target interventions 112 
and improve clinical and economic outcomes (13). When focusing on dHRQoL, it is of 113 
fundamental importance to hinder as far as possible the natural slow decline in longitudinal 114 
trajectories of HRQoL punctuated by episodes of serious exacerbations that lead to hospital 115 
admissions (14,15), or, in other words, to provide ‘upstream’ preventive care to patients in 116 
need before ‘downstream’ morbidity and expenditures occur (13). High-performance 117 
prognostic models may be used to detect patients in need of supportive care (e.g. geriatric 118 
assessment and medication review) (10–12,16). 119 
To the best of our knowledge, no dHRQoL prognostic model for older patients with multiple 120 
chronic conditions and polypharmacy exists. We therefore aimed to develop and validate a 121 
model to predict dHRQoL after six months of follow-up in older patients with at least one 122 
chronic condition and one chronic prescription, based on an individual participant data meta-123 
analysis (IPD-MA). We used the IPD from a previously harmonized database that contains 124 
comprehensive patient-related data on socio-demographics, morbidity, medication, functional 125 
status, and well-being from five recent cluster-randomized trials conducted in German and 126 
Dutch general practices. We chose a prognostic modelling approach based on IPD-MA because 127 
it offers both statistical and clinical advantages over other modelling techniques by permitting 128 
the assessment of generalizability. Furthermore, the increased sample size and case-mix 129 
variability it provides may reduce overfitting and thus improve external performance (17). 130 
131 
MATERIALS AND METHODS 132 
Source of data 133 
We harmonized individual participant data (IPD) from five cluster-randomized trials that were 134 
conducted in the Netherlands and Germany between 2009 and 2012 to optimize 135 
pharmacological treatment in older chronically ill patients (Supplemental Table 1). Although 136 
conducted in different health care systems, the included trials, namely ISCOPE (18), Opti-Med 137 
(19,20), PIL (Nederlands Trial Register, NTR2154) (21), PRIMUM (8,22), and RIME (Deutsches 138 
Register Klinischer Studien-ID, DRKS00003610), resemble each other in terms of key study 139 
characteristics. Four trials (PRIMUM, Opti-med, PIL, and RIME) compared a structured 140 
medication review consisting of several intervention components (i.e., complex interventions) 141 
with usual care, while ISCOPE used a functional geriatric approach to compare usual care with 142 
a proactive and integrated care plan. Details of the origin and preparation of the source data 143 
for the PROPERmed database (PRIMUM, Opti-Med, PIL, ISCOPE, RIME) will be published 144 
elsewhere. 145 
[About here link to: Supplemental Table 1 on Main characteristics of the included trials] 146 
Participants 147 
At baseline, we included general practice patients aged 60 years or older with at least one 148 
chronic condition and one chronic prescription. We defined chronic conditions in accordance 149 
with O´Halloran´s list (23), and chronic prescriptions in the same way as the included trials 150 
(two weeks duration in PRIMUM, two months in ISCOPE, and three months in Opti-Med, PIL 151 
and RIME). 152 
Outcome 153 
We defined dHRQoL as a decrease of at least five percent from baseline to six-month follow-up 154 
in the 5 dimensions 3 level version of EuroQoL (EQ-5D-3L), operationalized using a Likert score. 155 
We considered this cut-off as clinically relevant because it corresponds to several studies’ 156 
estimates of patients’ perceptions of minimal important difference (MID) (24–26). In two of 157 
the Dutch trials (ISCOPE and PIL), the question relating to the item “mobility” was slightly 158 
modified from the original instrument, as it was frequently a missing value in older Dutch 159 
populations due to misinterpretation (27). 160 
Prognostic variables 161 
For candidates at baseline, 87 prognostic variables relating to socio-demographics, lifestyle, 162 
morbidity, medication, functional status, and well-being were considered for inclusion in the 163 
modelling process. The allocation of patients to control and intervention groups was also 164 
considered. 165 
Socio-demographics and lifestyle 166 
We collected IPD on age, sex, living situation, and educational level (28) from the trials. 167 
Information on smoking status was provided in three (PRIMUM, PIL, and RIME) of the five 168 
trials.  169 
Morbidity 170 
We used the second version of the International Classification of Primary Care (ICPC-2) (29) to 171 
describe a common list of individual chronic conditions across trials (patient-reported in RIME; 172 
in all others we used physician-reported information) and used a modified version of the 173 
Diederichs list for morbidity count, which included 15 of the 17 conditions identified in a 174 
systematic review (i.e. dementia, kidney and peripheral artery disease were not provided in 175 
two of the five trials) (30). The Charlson comorbidity index (31) was provided in two of the 176 
trials (PRIMUM and RIME), but could not be calculated for the other trials (e.g. because no 177 
information was provided on condition severity).  178 
Medication 179 
Potentially inappropriate prescriptions and medication underuse were mainly assessed using 180 
patient-reported medication data (except from ISCOPE which provided physician-reported 181 
information) by applying the criteria used in the EU-PIM list (32), STOPP-START criteria (33), 182 
the high-risk prescribing criteria applied by Dreischulte et al. (34), the Anticholinergic Drug 183 
Scale (ADS) (35,36), the Drug Burden Index (DBI) as a count variable (as the dosage that would 184 
have allowed the calculation of the index score was not available in the majority of IPD (37–185 
39)), and Anticholinergic Drug Burden (ADB) (40).  186 
Functional status and well-being 187 
Trials used various instruments to measure functional status such as the Katz-15 (combination 188 
of KATZ-6 and Lawton IADL) questionnaire (41), the 13-item vulnerable elderly survey (VES-13) 189 
(42), and the Geriatric Giants VAS (GGV) scale (0-10) (43) developed ad hoc by one of the trials 190 
(Opti-Med). To standardize the metrics used in the scales of the instruments employed in the 191 
different trials, numerical values were subtracted from their overall mean (i.e., centred) and 192 
subsequently divided by their standard deviations (i.e., scaled) to obtain comparable values 193 
that would, however, require back-transformation for clinical interpretability. 194 
The trials assessed the presence of depressive symptoms using different questionnaires (the 195 
15-item Geriatric Depression Scale (GDS) (44,45), GDS-5 (46), SF-12 (47,48), and SF-36 (49). We196 
considered the standardized mean differences of the various instruments for the modelling 197 
approach. The presence of depressive symptoms was used as a binary variable for descriptive 198 
purposes and derived from the cut-offs of the original questionnaires used in the various trials. 199 
The presence of pain was defined as a binary variable using the categorical classification (no 200 
pain or any pain regardless of intensity) from the von Korff index (50), the SF-12 (47,48), the 201 
SF-36 (49), and the self-developed VAS scales or single questions used in two of the trials (i.e. 202 
Opti-Med, ISCOPE).  203 
Regarding HRQoL at baseline, we used the above described EQ-5D-3L index score (51). In 204 
addition, we considered the two independent subscales from the HRQoL Comorbidity Index 205 
(52–54) as prognostic variables (Supplemental Table 2). 206 
[About here link to: Supplemental Table 2 on Prognostic variables and their definitions] 207 
Sample size 208 
The sample size reflected the number of available observations in the included trials. In order 209 
to calculate achievable performance based on the available sample size, we applied the 210 
formulae for minimum sample sizes (55). As we applied the calculation retrospectively, the 211 
sample size calculation only has exploratory character. This was part of the process of 212 
developing multivariable prediction models to obtain estimates for the heuristic shrinkage 213 
factor caused by the number of candidate predictors (55). Based on the sample size of our 214 
complete-case analysis and the use of empirical estimates of C-statistics and event frequencies 215 
to approximate the prediction model Cox-Snell R-squared’s apparent performance (Cox-Snell 216 
R
2
 of 0.12), we would expect a heuristic shrinkage factor of 0.84, which we considered 217 
acceptable.  218 
Missing data 219 
In addition to the core analysis of complete cases, we conducted sensitivity analyses using the 220 
missing-indicator method (MIM) (56,57) and multiple imputation. For the latter, we conducted 221 
six multiple imputations (MI) in five iterations (58), and pooled them according to Rubin’s 222 
Rules (59). For the original trials, stratification was used to graphically explore missing data 223 
patterns (60,61). This revealed the various contributions of sporadically and systematically 224 
missing values (variable not recorded in the trials). We performed multi-level multiple 225 
imputation to adjust for within-trial and between-trial variability (62).  226 
When values were missing systematically, we did not consider the associated candidate 227 
prognostic variables in any of the trials (i.e. smoking status, Charlson comorbidity index). 228 
Statistical analysis methods 229 
Modelling framework to deal with within-study correlation and between-study heterogeneity in 230 
the IPD 231 
Prognostic model development and validation relied on an established framework for 232 
developing and evaluating clinical prediction models in an IPD-MA (17). By virtue of their 233 
origins in different independent trials, the clustered data structure first had to be addressed. A 234 
stratified intercept model was fitted, which provided a different baseline risk for each trial. 235 
This approach was selected over a random intercept model because the validity of the 236 
normality assumption for the random intercept in differing random effects models cannot be 237 
checked and is open to doubt when five trials are conducted in different health care systems. 238 
A generalized linear model was therefore chosen using the logit link function (i.e., logistic 239 
model). To improve interpretability, we used effect coding rather than dummy coding in order 240 
to estimate trial-specific baseline risks (63). This produces a global intercept (overall average) 241 
and shows the deviation from the average for each trial. While in a one-stage meta-analysis for 242 
model development and internal validation, the study indicators account for the origin of the 243 
data, each study serves as a validation sample in an applied internal-external cross validation 244 
(IECV) (17,64). 245 
Model development and variable selection 246 
When developing the model, we defined it structurally by selecting variables using the so-247 
called Least Absolute Shrinkage and Selection Operator (LASSO) (65). Age (assumed, like the 248 
other continuous variables, to be linearly associated with outcome), sex, and the effect-coded 249 
indicators reflecting the trials’ baseline risk, were not regularized. In order to obtain sparser 250 
models, we moved away from the default setting, which would have meant choosing the 251 
tuning parameter lambda as the value with the minimum mean cross-validated error (“optimal252 
penalty”). In preference, we decided to be stricter and chose the most regularized model, 253 
meaning that the error was within one standard error of the minimum (“1-se rule” (66)). 254 
Variable importance was derived from the ranks of the absolute values of the final 255 
(standardized) coefficients (65). For subsequent cases, the model formula obtained using the 256 
LASSO technique was applied to models that were refitted using unpenalized maximum 257 
likelihood. We additionally calculated a uniform shrinkage factor from bootstrap internal 258 
validation; the uniform shrinkage factor corresponds to one minus the average of all 259 
calibration slopes of each bootstrap model applied to the original IPD.    260 
Performance metrics 261 
Predictive performance was assessed by simultaneously using 250 bootstrap samples 262 
internally (67), and employing IECV to assess generalizability (17,64). Model performance in 263 
terms of discriminatory ability to differentiate patients with dHRQoL from the rest was 264 
quantified using the C-statistic (equivalent to the area under the receiver-operating 265 
characteristic curve, ROC). Performance metrics for model calibration to assess agreement 266 
between observed event frequencies and predicted probabilities were based on the slope of 267 
the calibration curve and calibration-in-the-large (CITL), and additionally inspected visually by 268 
means of calibration plots (68).  269 
Model validation 270 
With regard to internal bootstrap validation, the prediction model was developed de-novo for 271 
each of the 250 bootstrap samples, thus maintaining the proportions of the original trial data 272 
in the IPD. Performance metrics were calculated from models fitted to the bootstrap samples 273 
that were subsequently applied to the original IPD. The mean difference across all bootstrap 274 
samples was the estimated optimism, while the optimism-corrected performance metric was 275 
obtained by subtracting estimated optimism from the original apparent performance metric.  276 
In IECV loops in particular, CITL was used to reflect overall calibration. Mimicking the 277 
application in a new population, the IECV loop repeatedly selects variables and thus fits a 278 
prediction model in all but one of the IPD trials (i.e. training set), while also checking predictive 279 
performance in the omitted study (i.e. test set). We chose the conservative option of the 280 
average intercept of the IECV training set. As they are of special importance for external 281 
validation, we extracted the C-statistic and CITL estimate for each omitted study at each stage 282 
of the IECV loop (69). Based on the within-study correlation between the C-statistic and CITL 283 
obtained using a non-parametric bootstrap (70), the respective estimates were pooled using 284 
multivariate random-effects meta-analysis (71). Taking a Bayesian approach with an 285 
uninformative prior distribution, a multivariate t-distribution (of the pooled means and 286 
covariance matrix from the multivariate meta-analysis) was used as an approximate posterior 287 
distribution to assess the model’s combined discrimination and average calibration 288 
performance. Requiring at least modest discriminatory ability of 0.65 and a CITL between -0.1 289 
and 0.1, the proportion of samples from the posterior distributions that achieved this allowed 290 
us to calculate the probability of satisfying these requirements (70). 291 
Technical implementation and reporting 292 
All analyses were conducted using the R software environment in version 3.6.1 (R Foundation 293 
for Statistical Computing, Vienna, Austria) with the key packages of glmnet (65), metaphor 294 
(71), caret (72), mice (58), and pmsampsize (55). 295 
This research study was reported in accordance with the TRIPOD statement (Supplemental 296 
table 3) (73). 297 
[About here link to: Supplemental Table 3 on TRIPOD Checklist: Prediction Model Development 298 
and Validation]  299 
300 
RESULTS 301 
Of all eligible 4,561 patients from the PROPERmed database for whom multiple imputation 302 
datasets were available, 3,582 patients with full data for all candidate prognostic variables 303 
were included in the complete-case population (Figure 1). In this subset, the HRQoL of 1,046 304 
(29.2 %) patients deteriorated by at least five percent according to the EQ-5D-3L index at six-305 
month follow-up: 105 (27.6 %) patients from PRIMUM, 94 (24.4 %) from Opti-Med, 131 (29.2 306 
%) from PIL, 442 (32.8 %) from ISCOPE and 274 (26.9%) from RIME.  307 
The mean age of the complete-case population was 78 (SD 7) years; 58 % were women, 96 % 308 
lived at home, and 88 % had a low/medium level of education. The population had an average 309 
of 3 (SD 2) chronic conditions (multimorbidity) and 8 (SD 4) chronic prescriptions 310 
(polypharmacy). Seventy-eight percent of patients were taking three or more medications. 311 
Sixty-seven percent suffered from pain and 20 % had depressive symptoms. 312 
Table 1 and Supplemental table 4 show the prognostic variables both overall and stratified 313 
according to observed dHRQoL status in the complete-case population. In Supplemental Table 314 
5, prognostic variables are shown both overall and stratified according to the interventional 315 
status of the original trials in the complete-case population. Supplemental figures 1 and 2 316 
show the baseline HRQoL distribution across countries and study arms. 317 
[About here Figure 1 on Flow chart and schematic course of action]  318 
[About here Table 1 on Prognostic variables and statistically significant univariable associations 319 
with dHRQoL] 320 
[About here link to: Supplemental table 4 on Prognostic variables and univariable associations 321 
with dHRQoL] 322 
[About here link to: Supplemental table 5 on Candidate prognostic variables and outcome of 323 
the five randomized controlled trial stratified by interventional status] 324 
[About here link to: Supplemental figure 1 on Baseline HRQoL distribution across countries] 325 
[About here link to: Supplemental figure 2 on Baseline HRQoL distribution in study arms] 326 
When developing the prognostic model for dHRQoL using the candidates’ prognostic variables, 327 
variable selection using LASSO yielded a structural model with the items listed in Table 2. 328 
Refitting the LASSO-derived model formula to CC, MIM, and MI datasets yielded nearly 329 
identical performance metrics in terms of model discrimination (Figure 2A) and model 330 
calibration (Figure 2B). Variable importance metrics illustrated the predictive value of the 331 
individual prognostic variables (Table 2). Baseline quality of life and functional status showed 332 
the greatest prognostic relevance, with a relative contribution to the model’s performance of 333 
62% and 31% respectively (Figure 2C). Bootstrap internal validation from Table 2 yielded an 334 
optimism-corrected C-statistic of 0.71 (95 % confidence interval: 0.69 to 0.72) which was close 335 
to the C-statistic of 0.72 and indicated good discrimination. An optimism-corrected calibration 336 
slope of 0.88 (0.78 to 0.98) indicated moderate calibration. In an explorative analysis, we 337 
grouped the prognostic variables according to clinical origin; this process consistently revealed 338 
the considerable significance of functional status and well-being to discriminatory 339 
performance (Figure 2D), while the model derived using variable selection was comparable to 340 
full models in internal validation metrics. Between-study heterogeneity was clearly visible in 341 
the stratified trial intercepts (Table 2). The model performed well for all trials used as 342 
validation datasets in the IECV loop, with a pooled C-statistic of 0.68 (0.65 to 0.70), a CITL of 0 343 
(-0.13 to 0.13) (Figure 3) and between-study heterogeneity I
2
 of 24.6 % and 78.6 % 344 
respectively. We also obtained a joint probability of 75 % of achieving a C-statistic of 0.65 and 345 
CITL between -0.1 and 0.1 in an independent but similar population. 346 
[About here: Table 2 on Final multivariable analysis of dHRQoL at six-month follow-up] 347 
[About here: Figure 2 on model development and validation] 348 
[About here: Figure 3 on meta-analytical summary of IECV loop] 349 
 350 
DISCUSSION 351 
This is the first IPD-based prognostic model for dHRQoL in a population of older patients with 352 
multiple conditions (two or more) and polypharmacy (five or more prescriptions) in general 353 
practice. While the prognostic model discriminated well and demonstrated reasonable 354 
generalizability in the IECV, intercept recalibration to consider further populations of interest 355 
would nevertheless be necessary before implementation. Our model included a wide selection 356 
of prognostic variables related to demographics, prescribed medication, potentially 357 
inappropriate medication and omissions, functional status, and well-being, which all 358 
significantly contributed to the prediction of dHRQoL. Among them, baseline HRQoL (high face 359 
validity) was the most important, followed by functional status (well known to be associated 360 
with dHRQoL (74)). Simple counts of multimorbidity (30) and polypharmacy did not indicate 361 
that patients were at risk per se with regard to dHRQoL, contrary to what is found in the 362 
literature (7,75). 363 
Using an IPD-MA to create a model based on primary research data provided a suitable and 364 
comprehensive source of information that covered all relevant dimensions that are required in 365 
a prognostic model of dHRQoL. The case-mix variability of this database, which includes 366 
patients from two different health care contexts and involves a reasonable time frame to avoid 367 
limiting external validity, helped us achieve good model performance and promising 368 
generalizability. Thus, the IPD framework allowed the generalizability of the prediction model 369 
to be estimated, as well as the probability of adequate performance in an independent 370 
population. However, the IPD-MA-based modelling approach also entailed the loss of some 371 
information (e.g., the smoking status variable was systematically missing, and consideration of 372 
common chronic conditions was limited) and made it difficult to clinically interpret some 373 
prognostic variables (e.g., standardization of functional status measures). Furthermore, the 374 
exclusion criteria of a short life expectancy and dementia limit the generalizability of the 375 
findings. 376 
To the best of our knowledge, our dHRQoL prognostic model for older patients with chronic 377 
conditions and polypharmacy in general practice is the only one of its kind. Existing risk 378 
stratification tools that have been developed and validated to predict negative outcomes in 379 
older patients with multiple morbidities have focused mainly on predicting hospital (re-) 380 
admissions (76). The C-statistics of these tools varied between 0.5 and 0.85, with the highest 381 
C-statistics found in models that included functional status as an outcome (76). Two studies 382 
(77,78) that evaluated four risk tools with the aim of identifying people with multiple 383 
conditions that were at risk of reduced HRQoL were recently assessed in a NICE guideline 384 
review (79). All of these tools demonstrated poor discrimination and calibration in predicting 385 
dHRQoL, and their certainty of evidence according to GRADE (80) ranged from low to very low. 386 
To date and as far as we are aware, no relevant studies exist that predict dHRQoL in older 387 
populations based on polypharmacy or any other medication-related information. 388 
According to the results of the PROPERmed prognostic model, assessment of health-related 389 
quality of life and functional status might help physicians to detect patients with 390 
multimorbidity and polypharmacy at risk for a potentially preventable deterioration. However, 391 
for use in our model, the latter would have to be standardized to take into account mean 392 
values and deviation in the target population. Additionally, we recommend using shrunken 393 
estimates to multiply the effects of our prognostic variables with the uniform shrinkage factor 394 
obtained from internal bootstrap validation. It is also important to consider how best to 395 
choose the baseline risk for dHRQoL (intercept) in the new population. While for the original 396 
trials an average intercept appeared reasonable for IECV (between-study heterogeneity I
2
 of 397 
78.6 % in CITL), implementation in a completely new setting may require adjustments to 398 
account for outcome frequencies, or even complete re-estimation (17). Therefore, 399 
implementation of the PROPERmed dHRQoL model in a completely new setting will require 400 
taking the intermediate steps mentioned above, especially as data from the target population 401 
is likely to differ from our own. Furthermore, the PROPERmed dHRQoL model should undergo 402 
an impact assessment, whereby it is particularly important to evaluate its ability as a 403 
prognostic tool to prioritize (complex) interventions in general practice, and thus to determine 404 
whether it could actually help optimize medication regimens.  405 
 406 
CONCLUSION 407 
The first IPD-based prognostic model of dHRQoL in older patients with multiple chronic 408 
conditions and medication in general practice performed well in calibration, discrimination and 409 
might thus effectively assist in the identification of high-risk patients.  410 
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Figure 1: Flow chart and schematic course of action 
CC = Complete Cases; IPD = Individual Participant Data; LASSO = Least Absolute Shrinkage and 
Selection Operator; MI = Multiply Imputed; MIM = Missing-Indicator Method; dHRQoL = 
deterioration in Health-Related Quality of Life. 
Figure 2: Model development and validation. (A) By yielding receiver-operating characteristic 
(ROC) curves, the model’s estimates of sensitivity and specificity for calculated risks 
discriminate between patients with and without dHRQoL. ROC curves are visualized for the 
following study populations: complete cases (CC), one multiply imputed dataset (MI), and data 
added using the missing-indicator method (MIM). The added lines mark the median risk cut-off 
of 0.41, with a sensitivity of 72% and specificity of 59%. (B) Similarly, calibration curves are 
generated by plotting predicted event probabilities against (cumulative) event frequencies. (C) 
Scrutinizing the impact of model parameters, a variable importance plot highlights their 
relative contribution to model performance, adjusted in relation to the most important 
prognostic variable. (D) Exploring the influence of variable origin, we fitted models composed 
of variables that are sociodemographic and lifestyle-related alone (α), or combinations of α 
and morbidity-related (β), medication-related (γ) predictors, and / or predictors related to 
functional status and well-being (δ) in accordance with Table 1. Resulting estimates of C-
statistics are presented for bootstrap internal validation and internal-external cross-validation 
(IECV) if all available variables were included into the model (i.e., full model – grey circles) or 
only those having actually been selected during model development (black circles). 
Figure 3: Meta-analytic summary of model generalizability.  
A bivariate random-effects meta-analysis was conducted to determine the pooled 
performance metrics of C-statistics and calibration-in-the-large (CITL) from internal-external 
cross-validation (IECV), with the respective trial serving as the validation set for the model that 
was refitted in the remaining trials. The Forest plot visualizes trial-specific estimates and their 
pooled results.  
Supplemental figure 1: Baseline HRQoL distribution across countries. 
Boxplot of HRQoL measurements at baseline on the respective EQ5D scale of the country the 
original study came from. Distinct values from the original studies are superimposed to 
highlight between-study variability. 
Supplemental figure 2: Baseline HRQoL distribution in study arms. 
Boxplot of HRQoL measurements at baseline on the respective EQ5D scale of the country the 
original study came from, according to interventional status. Distinct values from the original 
studies are superimposed to highlight between-study variability. 
 
  
Table 1. Candidate prognostic variables and statistically significant univariable associations with dHRQoL 
 
Candidate prognostic variable 




n = 2,536 
Yes 
n = 1,046 
Sociodemographic and lifestyle-related  
Age - Mean (SD) 77.2 (6.8) 78.3 (6.9) < 0.001 
Sex (female) - Frequency (%) 1,449 (57.1) 627 (59.9) 0.122 
Living situation (Institutionalized living) - Frequency (%) 87 (3.4) 59 (5.6) 0.003 
Educational level - Frequency (%)  
- Low 1,018 (40.1) 472 (45.1)  
- Medium 1,206 (47.6) 469 (44.8) 0.024 
- High 312 (12.3) 105 (10.0) 0.011 
Morbidity-related  
Coronary heart disease - Frequency (%) 817 (32.2) 393 (37.6) 0.002 
Medication-related  
Drugs for acid-related disorders - Frequency (%) 950 (68.3) 441 (31.7) 0.009 
Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in 
moderate-severe COPD - STOPP G2 - Frequency (%) 
15 (0.6) 15 (1.4) 0.015 
START criteria* – Median (IQR) 1 (2) 1 (2) 0.002 
START criteria* (modified) - Frequency (%) 1,425 (56.2) 634 (60.6) 0.015 
Heart failure and/or documented coronary artery disease and NO ACE inhibitor - START A6 
- Frequency (%) 
255 (10.1) 160 (15.3) < 0.001 
Ischemic heart disease and NO beta-blocker - START A7 - Frequency (%) 203 (8.0) 117 (11.2) 0.003 
Diabetes and NO ACE inhibitor or ARB - START F1 - Frequency (%) 150 (5.9) 95 (9.1) 0.001 
Functional status and well-being-related    
Functional status – Mean (SD) -0.123 (0.92) 0.044 (0.99) < 0.001 
Depression ** – Frequency (%) 485 (19.1) 201 (19.2) 0.95 
Pain – Frequency (%) 1,728 (68.1) 675 (64.5) 0.037 
Health-related quality of life comorbidity index, mental *** – Median (IQR) 1 (1) 1 (1) 0.044 
Quality of life: EQ-5D, version 3L, Index value (baseline) – Mean (SD) 0.70 (0.26) 0.81 (0.19) < 0.001 
This table shows candidate prognostic variables stratified according to observed dHRQoL status and univariable associations. 
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blockers; ATC = anatomical therapeutic chemical; COPD = chronic obstructive 
pulmonary disease; IQR = interquartile range; SD = standard deviation; dHRQoL= deterioration in health-related quality of life. 
* Fifteen START criteria were considered. 
**Depression considered possible in case of a positive score on either of the two provided scales (GDS/SF). 
*** Score calculated considering a maximum count of 6 conditions/13 points. 
 
Table 2. Final multivariable analysis for dHRQoL at six-month follow-up 
 
Selected prognostic factor System of measurement Estimate* standard error p value 
(Intercept)**  -4.457 0.581 0.000 
Age Years 0.000 0.007 0.969 
Sex (male)  -0.175 0.084 0.037 
Coronary heart disease (Myocardial infarction 
and/or angina pectoris) - ICPC-2 codes K74, K75, 
K76 
ICPC-2 codes K74, K75, K76 0.216 0.094 0.022 
Drugs for acid-related disorders  ATC code A02 0.274 0.082 0.001 
Systemic corticosteroids rather than inhaled 
corticosteroids for maintenance therapy in 
moderate-severe COPD - STOPP criteria G2 
(ATC codes H02AB OR H02BX) AND (ICPC-2 codes 
R79, R95 OR R96) NOT (ATC codes R03BA OR 
R03AK) 
1.108 0.432 0.010 
START criteria count  15 START criteria were included  -0.003 0.036 0.934 
ACE inhibitor with heart failure and/or 
documented coronary artery disease - START 
criteria A6 
(ICPC-2 codes K74, K75, K76, K77) NOT (ATC codes 
C09A OR C09B OR C09C OR C09D) 
0.212 0.141 0.133 
ACE inhibitor or ARB (if intolerant of ACE 
inhibitor) in diabetes with evidence of renal 
disease i.e. dipstick proteinuria or 
microalbuminuria - START criteria F1 
(ICPC-2 codes T89 OR T90) NOT (ATC codes C09A 
OR C09B OR C09C OR C09D) 
0.386 0.159 0.015 
Functional status Standardized values taken from the VES-13, Katz-
15 and GG mobility instruments used in the 
original studies 
0.557 0.053 0.000 
Depression Cut-offs for diagnosis of depression taken from the 
GDS 15/5 or SF12/36 instruments 
0.363 0.112 0.001 
Mental Component Summary score from 
health-related quality of life comorbidity index  
Score calculated according to the modified 
instrument: maximum count 6 conditions, 13 
points 
0.072 0.032 0.026 
Quality of life: EQ-5D, version 3L, Index value 
(baseline)   
Time Trade-Off values for EQ-5D-3L in German and 
Dutch populations 
4.175 0.263 0.000 
 
Baseline risks of studies (estimates): RIME -0.136, Opti-Med -0.175, PRIMUM -0.165, PIL 0.000 and ISCOPE 0.476. 
 
ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blockers; ATC = anatomical therapeutic chemical; COPD = chronic obstructive 
pulmonary disease; GDS = geriatric depression scale; GG = geriatric giant; Katz-15; ICPC = international classification of primary care; MCS = Modified health-
related quality of life comorbidity index, mental; SF = short form survey; TTO = time trade-off; VES = vulnerable elders survey; dHRQoL= deterioration in 
health-related quality of life. 
*Estimate = Parameter estimate of the maximum-likelihood fitted logistic regression model (possibly to be multiplied with the uniform shrinkage factor of 
0.88). 
**Intercept = Overall baseline risk for dHRQoL. 






Removal of 53 patients with ≥ 33 % of 
missing values in key prognostic variables 
considered for dHRQoL prediction
Complete cases in 87 
prognostic variables
PROPERmed dHRQoL CC
(n = 3,582; 1,046 events) 
Generate missing indicator variables 
(prognostic only, no outcome)
PROPERmed dHRQoL MIM
(n = 3,784; 1,105 events)
PROPERmed dHRQoL MI






n = 4,508 n = 3,582 n = 3,784
Internal-External Cross-Validation (IECV)
ISCOPE: n = 1,597 (590 events)  n = 1,348 (442) n = 1,398 (463)
Opti-Med: n = 514 (128) n = 386 (94) n = 423 (101)
PIL: n = 698 (220) n = 448 (131) n = 495 (141)
PRIMUM: n = 502 (143) n = 381 (105) n = 433 (121)








































• Multimorbidity and polypharmacy increase the risk of deterioration in quality of life. 
• First IPD-based quality-of-life prognostic model for older multimorbid patients. 
• Model performed well in terms of discrimination, calibration and generalizability. 
• Baseline quality of life and functional status have the strongest prognostic power. 
• Quality of life/functionality appraisal might help identify high-risk patients. 
AUTHOR CONTRIBUTIONS 
JWB, MvdA, UT, WEH, HJT, PJME, GK, JJM, DKdG, RP, PPG, ADM and CM contributed to the 
design of the PROPERmed study. CM is the guarantor. AIGG and ADM wrote the first draft of 
the manuscript. JWB, MvdA, DBL, UT, HR, HJT, PJME and CM represent the five included trials 
and provided all data needed for the IPD-MA. AIGG and TSD developed the harmonized 
PROPERmed database; KMAS, HR and BF supported. ADM performed the statistical analysis 
with the support of RP, KIES and HR. All authors contributed to the manuscript and agreed on 
its publication. The corresponding author attests that all listed authors meet authorship 
criteria and that no others meeting the criteria were omitted. 
 
WHAT IS NEW 
Key findings 
The PROPERmed prognostic model of future deterioration in health-related quality of life in 
older patients with multiple conditions and medications performed well in discrimination, 
calibration, and showed promising generalizability. 
The strongest predictors in the model were health-related quality of life and functional status 
at baseline. 
 
What does this add to what is already known? 
PROPERmed-dHRQoL is the first prognostic model to predict deterioration in health-related 
quality of life in older patients with multiple conditions and medications that is based on an 
individual participant data meta-analysis. 
 
What is the implication, what should change now? 
External validation studies should confirm generalizability beyond internal-external cross-
validation. 
Measures of health-related quality of life and functional status at baseline, which proved to be 
the two prognostic variables that are of outstanding relative importance in the prognostic 
model, may help physicians to detect patients with multimorbidity and polypharmacy at risk 
for a potentially preventable deterioration. 
 
